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Clinical Review & Education

JAMA Otolaryngology–Head & Neck Surgery | Clinical Challenge | PATHOLOGY

Asymptomatic Septal Mass
Richard L. Arden, MD; Zachary H. Griggs, DO; Elizabeth A. Wey, MD
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A woman in her 40s presented with a 2-month history of a slowly enlarging, asymptomatic anterior septal mass. She denied a history of localized trauma, substance abuse, or prior
endonasal surgery. Examination revealed a nontender, 8-mm, pink-red, soft, fleshy growth
just posterior to the membranous septum near the nostril apex. Histopathological analysis
demonstrated a well-circumscribed submucosal lesion comprised of bland, round, syncytial cells, arranged in a concentric fashion around variably sized slit-like vascular spaces, a
minority of which were staghorn in appearance (Figure, A-C). No significant perivascular
hyalinization was identified. The overlying nasal mucosa and surrounding submucosal glands
were unremarkable. Immunohistochemical stains demonstrate the cellular population to
be strongly positive for smooth-muscle actin (SMA), muscle-specific actin, and CD34 (Figure,
D), but negative for B-catenin and epithelial membrane antigen.

Diagnosis
D. Myopericytoma

Discussion
The new World Health Organization (WHO) classification of soft tissue tumors (previously reported in 2002) was updated in 2013 and
jamaotolaryngology.com

Figure. Histopathology of
asymptomatic septal mass shows (A)
a well-circumscribed, unencapsulated
lesion based in the submucosa with
an intact overlaying squamous and
respiratory mucosa
(hematoxylin-eosin); (B) bland,
vaguely spindled cells arranged
around prominent thin-walled vessels
with a “staghorn” branching
configuration (hematoxylin-eosin);
(C) the lesional cells are oval to
spindle shaped with abundant
cytoplasm and ill-defined cell borders
(hematoxylin-eosin); (D) the lesional
cells are stained diffusely with myoid
markers, including smooth muscle
actin and muscle-specific actin
(muscle-specific actin stain).

WHAT IS YOUR DIAGNOSIS?

A. Glomus tumor
B. Myofibroma
C. Solitary fibrous tumor
D. Myopericytoma

now acknowledges that myofibroma and/or myofibromatosis represents morphological points along the spectrum of myopericytic
neoplasms.1 Myopericytoma (MPC) is a mesenchymal tumor derived from the perivascular myoid cell, sharing features with smoothmuscle and glomus cells.2 Previously encompassed under the broad
category of hemangiopericytomas, these perivascular myomas can
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be categorized based on the predominant histologic pattern: myofibromatosis, glomangiopericytoma, and myopericytoma.3 Ultimately, diagnosis is based on these characteristic morphological features and supportive immunohistochemistry, recognizing that some
overlap exists with the exception of glomangiopericytoma, which
is histologically distinct and occurs in the sinonasal region.
Myopericytoma occurs mainly in childhood to mid-adult years
with a male predominance and predilection for dermal and subcutaneous locations in the lower extremities. Of the roughly 15.0% that
occur in the head and neck, only 2.5% are represented in the nose
and paranasal sinuses, accounting for less than 1.0% of sinonasal tumors overall.4 This typically benign, slowly growing neoplasm, often presents as a solitary painless mass that can cause epistaxis and
nasal obstruction. On examination, the lesion appears nodular to polypoid, soft and fleshy, friable, circumscribed, possesses a gray-pink
to beefy red color, and can be mistaken for an inflammatory polyp.
Myopericytoma are well circumscribed (usually <2 cm) but unencapsulated neoplasms with bland and relatively monomorphic oval
to spindle-shaped cells that are arranged in a concentric or whorling perivascular pattern. They differ from glomus cells by their larger
size, more abundant cytoplasm, and lack of a clearly demarcated cell
border.2 Immunostaining is characteristically strong for vimentin and
SMA expression but limited to small vessels for CD34.3,5 Pericytes
are SMA positive. Staining is characteristically negative for EMA, cytokeratins, and usually desmin. By contrast, the rare sinonasal solitary fibrous tumor exhibits a patternless proliferation of spindle cells
admixed with variable amounts of ropy keloidal collagen, increased perivascular and stromal collagen, haphazardly arranged
cells, and thin-walled vascular spaces. Strong diffuse immunoreactivity for CD34 and CD99 is seen, with variably positive to absent
SMA expression.3,4,6 Unlike MPC, perivascular concentric growth
with accentuated perivenule myoid proliferation is not a prominent feature of myofibroma. Diagnosis of myofibroma is typically
based on a characteristic biphasic zonal architecture with pericytoid and myoid features, whose whorled multiple nodules may
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display prominent stromal hyalinization. Similar to MPC, glomus tumor (GT) is a pericytic neoplasm with immunoreactivity for smoothmuscle and muscle-specific actin, as well as usual negativity for CD34.
However, these are very rare in the sinonasal region, and classic GT
is morphologically composed of compact, uniform, polyhedral, epithelioid cells organized in sheets, nests, or cords, and usually do not
possess staghorn-like vessel proliferation.7 Admittedly, it is recognized that GT, particularly variants of GT (eg, glomangiomyoma), may
overlap with MPC and that clear distinction may not always be possible. In the past, most myopericytic neoplasms lacked welldefined genetic abnormalities, impeding their objective classification; however, recent studies have identified recurrent gene
abnormalities, including SRF-RELA fusions among a subset of cellular variant myofibromas and myopericytomas8 and fusions involving members of the NOTCH family among GTs.9 These and future
genetic discoveries will hopefully clarify the relationship among the
different myopericytic tumors and improve upon the current morphologic classification.
Standard treatment for MPC is complete local resection, which
prognostically has proven more important than tumor size or location. Despite this, local recurrence rates have been reported at 10%
to 20%4,7 and likely related to incomplete excision and deep soft
tissue lesions. While the vast majority of these neoplasms are benign with excellent prognosis, cases of malignant MPC have been
reported.10 Markers for poor prognosis and increased recurrence
rates (local and metastatic) include prominent mitotic activity (>4
of 10 per high-powered field), Ki-67 proliferation index greater
than 10%, focal necrosis, cellular atypia, and tumor size larger than
5 cm, similar to features for malignancy in solitary fibrous tumor.
Metastatic disease (typically disseminated hematogenously to lung,
liver, and bone) and disease-related mortality is extremely rare. Attributable to the generally radioresistant nature of MPC, palliative
radiation therapy has been reserved for unresectable and recurrent tumor. Chemotherapy has demonstrated limited efficacy and
considered for inoperable tumors or metastases.
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